NEW YORK — zPredicta said on Thursday that it has partnered with Laboratory Corporation of America to develop and commercialize tumor-specific preclinical models based on its 3D cell culture platform. zPredicta’s platform integrates organ-specific cellular and extracellular elements into 3D culture models for in vitro cancer drug testing.
SAN JOSE, Calif.–(BUSINESS WIRE)–zPREDICTA, Inc., the leading provider of tumor-specific 3D cell culture models for the in vitro testing of anti-cancer therapeutics, is pleased to announce that it has entered into a strategic collaboration with LabCorp, a leading global life sciences company. The agreement will support the adoption of zPREDICTA’s proprietary 3D cell culture platform for preclinical testing and research studies in the biopharmaceutical industry.
PALO ALTO, Calif.–(BUSINESS WIRE)–Science Exchange, the world’s leading marketplace for outsourced R&D, has announced that it is working with zPREDICTA to offer online access to its predictive cancer drug development and testing services.
California-based company zPREDICTA™ has created a novel technology that reconstructs physiologically-relevant organ-specific human microenvironments that help eliminate the guesswork from drug development. Meaningful drug discovery studies involve complex experiments that are not feasible to perform manually. Automation is the answer, improving accuracy, saving time and reducing the amount of compound used.
Current in vivo and in vitro models for testing cancer therapeutics don’t accurately model the progression of metastasis, which limits their ability to predict efficacy in patients. Ixchel’s (zPREDICTA) PD-3D system is a cell-based 3D model that mimics the spread of cancer in human tissues, and aims to predict the clinical success of cancer therapies more reliably than other models.
Ixchel Scientific, a startup launching out of our current class, is making a tool that aims to more accurately predict how cancer drugs will behave in the body by creating organ-specific testing environments.